Transfer of 45 million yuan of BZP to Aoxiang pharmaceutical

Zhengzhou University signed a patent transfer and research and development agreement with Zhejiang Aoxiang pharmaceutical industry representative Cerebrovascular disease is one of the three major diseases that cause human death Globally, about 4.6 million people die of cerebrovascular disease every year China is a region with a high incidence of stroke mortality According to the guidelines for the diagnosis and treatment of acute ischemic stroke in 2010, there are 7 million residents suffering from cerebrovascular diseases, 2 million new cerebrovascular diseases occur every year, and more than 1.5 million of them die According to Chang Junbiao, two of the three kinds of drugs commonly used in China have no significant therapeutic effect, which will cause adverse reactions The "brozopine sodium", a new drug developed by him, is a new compound developed on the basis of another drug, which is intended to be used in the treatment of mild and moderate acute ischemic cerebral infarction It is understood that the new drug, which took 13 years and was developed with more than 50 people's wisdom, is expected to enter the clinical practice in April and may next year, and can be used by patients after the third phase of clinical treatment At present, the commonly used therapeutic drugs are divided into three categories: the first one is to improve cerebral circulation, the second one is to protect nerves, and the third one is butylphthalide The first kind of drugs and the second kind of drugs are either not significantly treated or have serious adverse reactions, such as bleeding, liver function abnormality, etc., and the patients have poor tolerance The third kind of butylphthalide has the functions of increasing cerebral blood flow and reconstructing microcirculation in ischemic area, protecting mitochondrial function, improving energy metabolism after global cerebral ischemia, and reducing the degree of nerve function damage It involves many links of cerebral ischemia pathology and has a strong therapeutic effect on ischemic stroke Meanwhile, it also has some changes on brain injury, convulsion, memory disorder and other diseases Good and protective function is a single structure with excellent security In addition, it has a variety of pharmacological effects, can comprehensively treat ischemic stroke, significantly reduce the loss of neurological function after infarction, and improve the living ability of patients However, it may cause liver dysfunction and gastrointestinal reactions in clinical use "BZP" is a new compound developed on the basis of butylphthalide Compared with butylphthalide, the dosage needed is smaller and the effect is better At the same time, there is no adverse reaction of butylphthalide In animal experiments, it showed excellent protective effect, antiplatelet aggregation and alleviating brain tissue damage caused by cerebral artery occlusion, and no side effects such as excitation and bleeding It has a good preventive and therapeutic effect on the heart and brain ischemia, as well as anti platelet aggregation, treatment of heart and brain artery occlusion, improvement of heart and brain microcirculation and other pharmacological effects "BZP", a new drug, originated from natural compound apigenin, has its unique structural characteristics First, it is a new drug with independent intellectual property rights in the field of cerebrovascular in China It can increase the cerebral flow in the ischemic area, reconstruct the microcirculation in the ischemic area, reduce the area of the brain ridge, protect the mitochondria, improve the energy metabolism after cerebral ischemia, and alleviate it Brain edema caused by local cerebral ischemia has clear target; second, it is a solid drug with good solubility, convenient preparation, low cost and good bioavailability; third, it can improve the stability of enzyme and acid glycolysis of drugs, and is not easy to be oxidized and metabolized in vivo, with long half-life, which will not cause liver function abnormality and transaminase rise in clinical use High toxicity, small side effects, no gastrointestinal reactions and other adverse reactions Zheng Yongkou, Secretary of the Party committee of Zhengzhou University, said at the signing ceremony: "the signing of the agreement between Zhengzhou University and Zhejiang Aoxiang pharmaceutical industry marks a new stage of cooperation between the two sides As the transferor of patent technology, Zhengzhou University will earnestly implement the cooperation agreement and take practical measures to ensure the smooth development of project transfer and research and development It is hoped that through the cooperation between the two sides, new and greater contributions will be made to promote the development of China's medical and health undertakings " Professor Chang Junbiao has been engaged in the research of pharmaceutical synthetic chemistry for a long time He has successively undertaken the National Science Fund for Distinguished Young Scholars, the 11th five year plan, the 12th Five Year Plan and the major national science and technology projects of major new drug creation FNC, a new anti AIDS drug, has been successfully transferred and obtained national and international patents, with independent intellectual property rights and innovation Azvudine, a world leading new drug for AIDS treatment, was approved by the State Food and Drug Administration for clinical trials in April 2013 About Zhejiang Aoxiang pharmaceutical: Zhejiang AoXiang Pharmaceutical Co., Ltd is located on the coast of the East China Sea (in Taizhou Linhai medical and Chemical Park), which is a development and growth company integrating research and development, production and operation of APIs and preparations The company covers an area of more than 130 mu, with a total investment of 249515600 yuan Zheng Zhiguo, Zhejiang AoXiang Pharmaceutical Co., Ltd.: innovative technology leads the growth of enterprises In Taizhou pharmaceutical industry, there are many young forces who have made brilliant achievements in just a few years Aoxiang is one of them In 2008, Zheng Zhiguo led seven or eight people to start Aoxiang pharmaceutical After five or six years, the company has developed from less than one million yuan of assets to more than 100 million yuan of annual sales Zheng Zhiguo said he relies on enterprise innovation In 1995, after graduating from zhengzhiguo University, he was engaged in pharmaceutical and chemical work He started as a pharmacist and grew into an entrepreneur who managed a company with hundreds of millions of assets Zheng Zhiguo and his team always believe that innovation is the first driving force of enterprise development Zheng Zhiguo said that when he founded Aoxiang in 2008, he had only a few hundred thousand yuan of working capital, but he did not grudge the talents In order to invite a professional from FDA to work, Aoxiang pharmaceutical industry is willing to offer a high salary of $200 / hour In addition, Aoxiang pharmaceutical also has extensive cooperation with Shanghai Institute of organic chemistry, Beijing Institute of chemistry, Zhejiang University and other universities and scientific research institutions In May 2010, Zheng Zhiguo made another important decision He led Aoxiang and Academician Wu Yangjie of Zhengzhou University to set up the first academician expert workstation in Taizhou City, and introduced academician experts and their innovation teams to the enterprise After the academician expert team settled in, the first project was to improve the production process of Aoxiang phenylacetic acid derivatives At that time, the price of the product was generally 4800 yuan per kilogram, but the manufacturer could not make money Through scientific and technological innovation, the workstation reduced the process from 6 steps to 2 steps, saving time and increasing production capacity Aoxiang pharmaceutical's quotation dropped to 1400 yuan per kilogram, the lowest in the world, but its net profit was 20% The company became the world's largest supplier of the product, accounting for 80% of the market share With the first experience, Zheng Zhiguo and the academician and expert team launched a second project, entecavir, a drug for the treatment of hepatitis B the workstation simplified the process from 13 steps to 5 steps, with a purity of 99.97%, 98% higher than that of other suppliers, and the price was only $400 per gram, one tenth of the price quoted by foreign suppliers At present, the project has applied for invention patents in 8 countries and regions including China, the United States, Europe and Japan, and plans to apply for invention patents in 22 other countries and regions The industrial production of this drug is of great significance to the treatment of hepatitis B in China In addition, with his own professional technology and years of practical experience, Zheng Zhiguo led the team to develop new products and innovative processes one after another For example, new synthetic methods have been introduced for products such as prenast, montelukast, prostaglandin series, and miglitol, which play an important role in promoting the technological progress and development of Taizhou pharmaceutical industry and improving the level of drug use at home and abroad Zheng Zhiguo said that at present, Taizhou's pharmaceutical and chemical industry has more and more varieties, higher grades and stronger international competitiveness However, on the other hand, some "low, small and scattered" enterprises, in order to win the immediate interests, take passive pollution control or other illegal means to compete at low prices, which damages the interests of the industry He believes that the merger and reorganization of Taizhou's medical and chemical industry will be inevitable in the future, and the unreasonable product structure and insufficient product extension are the main problems of Taizhou's chemical API enterprises Although the prospect of Taizhou API market is good, from the perspective of industrial upgrading, API enterprises should pay more attention to the development of preparations in the process of entering the high-end market, and preparation production should be the strategic goal of API enterprises.